Dapagliflozin benefits consistent in HF for patients with, without gout

The benefit of dapagliflozin was consistent among adults with HF with and without gout and was associated with reduced initiation of new treatments for hyperuricemia and gout, according to a post hoc analysis of DAPA-HF and DELIVER.
“There is a consensus that the treatment of gout is suboptimal, with up to 70% of patients having recurring flares,” John J.V. McMurray, MD, professor of cardiology at the Institute of Cardiovascular and Medical Sciences at University of Glasgow in Scotland, and colleagues wrote in JAMA Cardiology. “SGLT2 inhibitors, a foundational treatment for

The benefit of dapagliflozin was consistent among adults with HF with and without gout and was associated with reduced initiation of new treatments for hyperuricemia and gout, according to a post hoc analysis of DAPA-HF and DELIVER.
“There is a consensus that the treatment of gout is suboptimal, with up to 70% of patients having recurring flares,” John J.V. McMurray, MD, professor of cardiology at the Institute of Cardiovascular and Medical Sciences at University of Glasgow in Scotland, and colleagues wrote in JAMA Cardiology. “SGLT2 inhibitors, a foundational treatment for